Journal of the National Cancer Institute
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.
Alison M Schram, Soo-Ryum Yang, Genessa Kahn, Rogelio Velasco, Matteo Repetto, Richard Kinh Gian Do, Sara DiNapoli, Purvil Sukhadia, Megan Troxel, Kerem Ozcan, Zeynep Tarcan, Marc Ladanyi, James J Harding, Alexander Drilon, Olca Basturk
Published: 202510.1093/jnci/djaf361
Abstract
BACKGROUND: NRG1 fusions are unique oncogenic drivers that activate the HER3/HER2/PI3K pathway. The FDA granted Accelerated Approval to a HER2/HER3 antibody, zenocutuzumab, for treatment of NRG1 fusion-positive (NRG1+) non-small-cell lung and pancrea…
Preview only. Read the full abstract at the source